Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CONSUMER TECHNOLOGY ASSOCIATION via MCDERMOTT+ LLC
2026 · third_quarter · 3T
Issues relating to healthcare innovation, including digital health and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMBER HEALTH via MCDERMOTT+ LLC
2026 · third_quarter · 3T
Source: Senate LDA
Issues relating to Medicaid fraud initiatives and Medicaid reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
CONSUMER TECHNOLOGY ASSOCIATION via MCDERMOTT+ LLC
2026 · second_quarter · Q2
Issues relating to healthcare innovation, including digital health and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMBER HEALTH via MCDERMOTT+ LLC
2026 · second_quarter · Q2
Issues relating to Medicaid fraud initiatives and Medicaid reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
CAMBER HEALTH via MCDERMOTT+ LLC
2026 · first_quarter · Q1
Issues relating to Medicaid fraud initiatives and Medicaid reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES
CAMBER HEALTH via MCDERMOTT+ LLC
2026 · first_quarter · RR
Issues relating to Medicaid fraud initiatives and Medicaid reimbursement.
PATIENTS FOR AFFORDABLE DRUGS NOW via MCDERMOTT+ LLC
2026 · first_quarter · Q1
Issues related to prescription drug competition and pricing.
Issues related to prescription drug competition, pricing and pharmacy benefit management reforms.
Issues related to prescription drug competition and pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via MCDERMOTT+ LLC
2026 · first_quarter · Q1
Issues relating to healthcare innovation, including digital health and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PATIENTS FOR AFFORDABLE DRUGS NOW via MCDERMOTT+
2025 · fourth_quarter · Q4
Issues related to prescription drug competition and pricing.
Issues related to prescription drug competition and pricing.
Issues related to prescription drug competition, pricing and pharmacy benefit management reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via MCDERMOTT+
2025 · fourth_quarter · Q4
Issues relating to healthcare innovation, including digital health and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PATIENTS FOR AFFORDABLE DRUGS NOW via MCDERMOTT+
2025 · third_quarter · Q3
Issues related to prescription drug competition and pricing.
Issues related to prescription drug competition and pricing.
Issues related to prescription drug competition, pricing and pharmacy benefit management reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE